Literature DB >> 11377013

A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma.

F H Shirazi1, G Bahrami, D J Stewart, E Tomiak, F Delorme, D Noel, R Goel.   

Abstract

A rapid, simple and sensitive isocratic High Performance Liquid Chromatography (HPLC) method was developed to measure the concentration of etoposide in plasma samples with UV detection at 220 nm. The method uses a Bondapac C18 column at 60 degrees C. The mobile phase consists of Methanol: water (45:55 v/v) at a flow rate of 2.8 ml/min. Phenacetin was used as an internal standard. The plasma samples were extracted using ether with the organic layer evaporated under nitrogen. The residue was dissolved in 200 microl methanol with 20 microl injected into the HPLC column. The extraction method showed a recovery of 91.5+/-3% for etoposide. In this system, the retention time of phenacetin and etoposide were 3.3 and 4.4 min, respectively. The limit of detection of etoposide in plasma is 20 ng/ml and the limit of quantitation is 40 ng/ml. This analytical method has very good reproducibility (8.1% between-day variability at a concentration of 50 ng/ml). It is a fast, sensitive and economic method applicable for clinical and pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377013     DOI: 10.1016/s0731-7085(00)00520-3

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.

Authors:  William R Schelman; Tabraiz A Mohammed; Anne M Traynor; Jill M Kolesar; Rebecca M Marnocha; Jens Eickhoff; Michael Keppen; Dona B Alberti; George Wilding; Naoko Takebe; Glenn Liu
Journal:  Invest New Drugs       Date:  2013-07-17       Impact factor: 3.850

2.  A validated stability-indicating LC method for estimation of etoposide in bulk and optimized self-nano emulsifying formulation: Kinetics and stability effects.

Authors:  Naseem Akhtar; Sushama Talegaonkar; Roop Kishan Khar; Manu Jaggi
Journal:  Saudi Pharm J       Date:  2012-01-24       Impact factor: 4.330

3.  Development and evaluation of sustained-release etoposide-loaded poly(ε-caprolactone) implants.

Authors:  Ana Gabriela Reis Solano; Adriana de Fátima Pereira; Flavia Carmo Horta Pinto; Letícia Gonçalves Resende Ferreira; Leandro Augusto de Oliveira Barbosa; Silvia Ligório Fialho; Patrícia Santiago de Oliveira Patricio; Armando da Silva Cunha; Gisele Rodrigues da Silva; Gérson Antônio Pianetti
Journal:  AAPS PharmSciTech       Date:  2013-05-11       Impact factor: 3.246

4.  Prognostic values of filamin-A status for topoisomerase II poison chemotherapy.

Authors:  Jingyin Yue; Shijie Lan; Changji Yuan; Zhiyuan Shen
Journal:  Int J Biol Sci       Date:  2012-02-29       Impact factor: 6.580

5.  Toxicogenomics of nanoparticulate delivery of etoposide: potential impact on nanotechnology in retinoblastoma therapy.

Authors:  Moutushy Mitra; Fahima Dilnawaz; Ranjita Misra; Anju Harilal; Rama Shenkar Verma; Sanjeeb K Sahoo; Subramanian Krishnakumar
Journal:  Cancer Nanotechnol       Date:  2010-12-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.